MyMD Pharmaceuticals (MyMD Pharmaceuticals) GF Value Rank : 0 (As of Jun. 18, 2024)

View and export this data going back to 2021. Start your Free Trial

What is MyMD Pharmaceuticals GF Value Rank?

MyMD Pharmaceuticals has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

MyMD Pharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of MyMD Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

MyMD Pharmaceuticals (MyMD Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MyMD Pharmaceuticals Inc (NAS:MYMD) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

DQS:Germany DQS:Germany

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mymd.com

MyMD Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. It is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-1R is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and a monoamine oxidase enzyme type B.

Executives

Paul Rivard	officer: EVP of Operations, GC	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Caroline C Williams	10 percent owner	324 SOUTH HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Adam Kaplin	officer: Chief Scientific Officer	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Jude Uzonwanne	director	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Craig Eagle	director	POST OFFICE BOX 4590, NEW YORK NY 10163
Chapman Christopher C Jr	director, officer: President, Chief Med. Officer	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Ian Rhodes	officer: Interim CFO	1375 KINGS HIGHWAY EAST, FAIRFIELD CT 06824
Stuart M Benson	officer: Chief Financial Officer	EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp	10 percent owner	28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber	10 percent owner	C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Robert C Schroeder	director	37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Howard Yeaton	officer: CEO, CFO	79 LLOYD ROAD, HOHOKUS NJ 07423
Tarbox Richard C Iii	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Christopher C Schreiber	director	AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086